APO Research
Talk to an analyst

APO RESEARCH · REPORT

PCSK9 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global PCSK9 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchPCSK9 Inhibitors Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal PCSK9 Inhibitors Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal PCSK9 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PCSK9 Inhibitors Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal PCSK9 Inhibitors Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global PCSK9 Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for PCSK9 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PCSK9 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PCSK9 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for PCSK9 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PCSK9 Inhibitors include Sanofi, Novartis, Merck, Roche, Eli Lilly, Pfizer, Daiichi Sankyo, Amgen and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PCSK9 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PCSK9 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PCSK9 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PCSK9 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

PCSK9 Inhibitors Segment by Company

Sanofi

Novartis

Merck

Roche

Eli Lilly

Pfizer

Daiichi Sankyo

Amgen

AstraZeneca

Ionis Pharmaceuticals

Cyon Therapeutics

BMS

Alnylam

Affiris

PCSK9 Inhibitors Segment by Type

Praluent(Alirocumab)

Bococizumab

Epatha(Evolocumab)

Others

PCSK9 Inhibitors Segment by Application

Clinical Application

Drug Development

Other

PCSK9 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PCSK9 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PCSK9 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PCSK9 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PCSK9 Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PCSK9 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PCSK9 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PCSK9 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PCSK9 Inhibitors Industry Trends Table 2. PCSK9 Inhibitors Industry Drivers Table 3. PCSK9 Inhibitors Industry Opportunities and Challenges Table 4. PCSK9 Inhibitors Industry Restraints Table 5. Global PCSK9 Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PCSK9 Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PCSK9 Inhibitors Sales by Manufacturers (k units) & (2021-2026) Table 8. Global PCSK9 Inhibitors Sales Market Share by Manufacturers Table 9. Global PCSK9 Inhibitors Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global PCSK9 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PCSK9 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PCSK9 Inhibitors Manufacturers, Product Type & Application Table 13. Global PCSK9 Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PCSK9 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Praluent(Alirocumab) Table 17. Major Manufacturers of Bococizumab Table 18. Major Manufacturers of Epatha(Evolocumab) Table 19. Major Manufacturers of Others Table 20. Global PCSK9 Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global PCSK9 Inhibitors Sales by Type (2021-2026) & (k units) Table 22. Global PCSK9 Inhibitors Sales by Type (2027-2032) & (k units) Table 23. Global PCSK9 Inhibitors Sales Market Share by Type (2021-2026) Table 24. Global PCSK9 Inhibitors Sales Market Share by Type (2027-2032) Table 25. Global PCSK9 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global PCSK9 Inhibitors Revenue by Type (2021-2026) & (k units) Table 27. Global PCSK9 Inhibitors Revenue by Type (2027-2032) & (k units) Table 28. Global PCSK9 Inhibitors Revenue Market Share by Type (2021-2026) Table 29. Global PCSK9 Inhibitors Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Clinical Application Table 31. Major Manufacturers of Drug Development Table 32. Major Manufacturers of Other Table 33. Global PCSK9 Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global PCSK9 Inhibitors Sales by Application (2021-2026) & (k units) Table 35. Global PCSK9 Inhibitors Sales by Application (2027-2032) & (k units) Table 36. Global PCSK9 Inhibitors Sales Market Share by Application (2021-2026) Table 37. Global PCSK9 Inhibitors Sales Market Share by Application (2027-2032) Table 38. Global PCSK9 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global PCSK9 Inhibitors Revenue by Application (2021-2026) & (k units) Table 40. Global PCSK9 Inhibitors Revenue by Application (2027-2032) & (k units) Table 41. Global PCSK9 Inhibitors Revenue Market Share by Application (2021-2026) Table 42. Global PCSK9 Inhibitors Revenue Market Share by Application (2027-2032) Table 43. Global PCSK9 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global PCSK9 Inhibitors Sales by Region (2021-2026) & (k units) Table 45. Global PCSK9 Inhibitors Sales Market Share by Region (2021-2026) Table 46. Global PCSK9 Inhibitors Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global PCSK9 Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 48. North America PCSK9 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 50. North America PCSK9 Inhibitors Sales by Country (2027-2032) & (k units) Table 51. Europe PCSK9 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 53. Europe PCSK9 Inhibitors Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific PCSK9 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific PCSK9 Inhibitors Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa PCSK9 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa PCSK9 Inhibitors Sales by Country (2027-2032) & (k units) Table 60. Global PCSK9 Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global PCSK9 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 62. Global PCSK9 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 63. Global PCSK9 Inhibitors Revenue Market Share by Region (2021-2026) Table 64. Global PCSK9 Inhibitors Revenue Market Share by Region (2027-2032) Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sanofi PCSK9 Inhibitors Product Portfolio Table 69. Sanofi Recent Development Table 70. Novartis Company Information Table 71. Novartis Business Overview Table 72. Novartis PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Novartis PCSK9 Inhibitors Product Portfolio Table 74. Novartis Recent Development Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Merck PCSK9 Inhibitors Product Portfolio Table 79. Merck Recent Development Table 80. Roche Company Information Table 81. Roche Business Overview Table 82. Roche PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Roche PCSK9 Inhibitors Product Portfolio Table 84. Roche Recent Development Table 85. Eli Lilly Company Information Table 86. Eli Lilly Business Overview Table 87. Eli Lilly PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Eli Lilly PCSK9 Inhibitors Product Portfolio Table 89. Eli Lilly Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Pfizer PCSK9 Inhibitors Product Portfolio Table 94. Pfizer Recent Development Table 95. Daiichi Sankyo Company Information Table 96. Daiichi Sankyo Business Overview Table 97. Daiichi Sankyo PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Daiichi Sankyo PCSK9 Inhibitors Product Portfolio Table 99. Daiichi Sankyo Recent Development Table 100. Amgen Company Information Table 101. Amgen Business Overview Table 102. Amgen PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Amgen PCSK9 Inhibitors Product Portfolio Table 104. Amgen Recent Development Table 105. AstraZeneca Company Information Table 106. AstraZeneca Business Overview Table 107. AstraZeneca PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. AstraZeneca PCSK9 Inhibitors Product Portfolio Table 109. AstraZeneca Recent Development Table 110. Ionis Pharmaceuticals Company Information Table 111. Ionis Pharmaceuticals Business Overview Table 112. Ionis Pharmaceuticals PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Ionis Pharmaceuticals PCSK9 Inhibitors Product Portfolio Table 114. Ionis Pharmaceuticals Recent Development Table 115. Cyon Therapeutics Company Information Table 116. Cyon Therapeutics Business Overview Table 117. Cyon Therapeutics PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Cyon Therapeutics PCSK9 Inhibitors Product Portfolio Table 119. Cyon Therapeutics Recent Development Table 120. BMS Company Information Table 121. BMS Business Overview Table 122. BMS PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. BMS PCSK9 Inhibitors Product Portfolio Table 124. BMS Recent Development Table 125. Alnylam Company Information Table 126. Alnylam Business Overview Table 127. Alnylam PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Alnylam PCSK9 Inhibitors Product Portfolio Table 129. Alnylam Recent Development Table 130. Affiris Company Information Table 131. Affiris Business Overview Table 132. Affiris PCSK9 Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Affiris PCSK9 Inhibitors Product Portfolio Table 134. Affiris Recent Development Table 135. Key Raw Materials Table 136. Raw Materials Key Suppliers Table 137. PCSK9 Inhibitors Distributors List Table 138. PCSK9 Inhibitors Customers List Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. PCSK9 Inhibitors Product Image Figure 2. Global PCSK9 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PCSK9 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global PCSK9 Inhibitors Sales (2021-2032) & (k units) Figure 5. Global PCSK9 Inhibitors Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 PCSK9 Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Praluent(Alirocumab) Image Figure 9. Bococizumab Image Figure 10. Epatha(Evolocumab) Image Figure 11. Others Image Figure 12. Global PCSK9 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global PCSK9 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global PCSK9 Inhibitors Sales Market Share by Type (2021-2032) Figure 15. Global PCSK9 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global PCSK9 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global PCSK9 Inhibitors Revenue Market Share by Type (2021-2032) Figure 18. Clinical Application Image Figure 19. Drug Development Image Figure 20. Other Image Figure 21. Global PCSK9 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global PCSK9 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global PCSK9 Inhibitors Sales Market Share by Application (2021-2032) Figure 24. Global PCSK9 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global PCSK9 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global PCSK9 Inhibitors Revenue Market Share by Application (2021-2032) Figure 27. North America PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America PCSK9 Inhibitors Sales Market Share by Country (2021-2032) Figure 29. U.S. PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe PCSK9 Inhibitors Sales Market Share by Country (2021-2032) Figure 34. Germany PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 35. France PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific PCSK9 Inhibitors Sales Market Share by Country (2021-2032) Figure 41. China PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 45. India PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa PCSK9 Inhibitors Sales Market Share by Country (2021-2032) Figure 49. Brazil PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile PCSK9 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global PCSK9 Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global PCSK9 Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America PCSK9 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. North America PCSK9 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe PCSK9 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Europe PCSK9 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific PCSK9 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific PCSK9 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa PCSK9 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa PCSK9 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. PCSK9 Inhibitors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. PCSK9 Inhibitors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Praluent(Alirocumab)
  • Bococizumab
  • Epatha(Evolocumab)
  • Others
Applications
  • Clinical Application
  • Drug Development
  • Other
Companies covered
  • Sanofi
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Daiichi Sankyo
  • Amgen
  • AstraZeneca
  • Ionis Pharmaceuticals
  • Cyon Therapeutics
  • BMS
  • Alnylam
  • Affiris

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PCSK9 Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PCSK9 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PCSK9 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PCSK9 Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PCSK9 Inhibitors Market Dynamics
  1. 2.1 PCSK9 Inhibitors Industry Trends
  2. 2.2 PCSK9 Inhibitors Industry Drivers
  3. 2.3 PCSK9 Inhibitors Industry Opportunities and Challenges
  4. 2.4 PCSK9 Inhibitors Industry Restraints
3 PCSK9 Inhibitors Market by Manufacturers
  1. 3.1 Global PCSK9 Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PCSK9 Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global PCSK9 Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PCSK9 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PCSK9 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PCSK9 Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global PCSK9 Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PCSK9 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PCSK9 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PCSK9 Inhibitors Tier 1, Tier 2, and Tier 3
4 PCSK9 Inhibitors Market by Type
  1. 4.1 PCSK9 Inhibitors Type Introduction
  2. 4.1.1 Praluent(Alirocumab)
  3. 4.1.2 Bococizumab
  4. 4.1.3 Epatha(Evolocumab)
  5. 4.1.4 Others
  6. 4.2 Global PCSK9 Inhibitors Sales by Type
  7. 4.2.1 Global PCSK9 Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global PCSK9 Inhibitors Sales by Type (2021-2032)
  9. 4.2.3 Global PCSK9 Inhibitors Sales Market Share by Type (2021-2032)
  10. 4.3 Global PCSK9 Inhibitors Revenue by Type
  11. 4.3.1 Global PCSK9 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global PCSK9 Inhibitors Revenue by Type (2021-2032)
  13. 4.3.3 Global PCSK9 Inhibitors Revenue Market Share by Type (2021-2032)
5 PCSK9 Inhibitors Market by Application
  1. 5.1 PCSK9 Inhibitors Application Introduction
  2. 5.1.1 Clinical Application
  3. 5.1.2 Drug Development
  4. 5.1.3 Other
  5. 5.2 Global PCSK9 Inhibitors Sales by Application
  6. 5.2.1 Global PCSK9 Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PCSK9 Inhibitors Sales by Application (2021-2032)
  8. 5.2.3 Global PCSK9 Inhibitors Sales Market Share by Application (2021-2032)
  9. 5.3 Global PCSK9 Inhibitors Revenue by Application
  10. 5.3.1 Global PCSK9 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global PCSK9 Inhibitors Revenue by Application (2021-2032)
  12. 5.3.3 Global PCSK9 Inhibitors Revenue Market Share by Application (2021-2032)
6 Global PCSK9 Inhibitors Sales by Region
  1. 6.1 Global PCSK9 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PCSK9 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global PCSK9 Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global PCSK9 Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PCSK9 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PCSK9 Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PCSK9 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PCSK9 Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PCSK9 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PCSK9 Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PCSK9 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PCSK9 Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PCSK9 Inhibitors Revenue by Region
  1. 7.1 Global PCSK9 Inhibitors Revenue by Region
  2. 7.1.1 Global PCSK9 Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PCSK9 Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global PCSK9 Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global PCSK9 Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PCSK9 Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America PCSK9 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PCSK9 Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe PCSK9 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PCSK9 Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PCSK9 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PCSK9 Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PCSK9 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi PCSK9 Inhibitors Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis PCSK9 Inhibitors Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck PCSK9 Inhibitors Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche PCSK9 Inhibitors Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly PCSK9 Inhibitors Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer PCSK9 Inhibitors Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Daiichi Sankyo
  38. 8.7.1 Daiichi Sankyo Company Information
  39. 8.7.2 Daiichi Sankyo Business Overview
  40. 8.7.3 Daiichi Sankyo PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Daiichi Sankyo PCSK9 Inhibitors Product Portfolio
  42. 8.7.5 Daiichi Sankyo Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen PCSK9 Inhibitors Product Portfolio
  48. 8.8.5 Amgen Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca PCSK9 Inhibitors Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Ionis Pharmaceuticals
  56. 8.10.1 Ionis Pharmaceuticals Company Information
  57. 8.10.2 Ionis Pharmaceuticals Business Overview
  58. 8.10.3 Ionis Pharmaceuticals PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ionis Pharmaceuticals PCSK9 Inhibitors Product Portfolio
  60. 8.10.5 Ionis Pharmaceuticals Recent Developments
  61. 8.11 Cyon Therapeutics
  62. 8.11.1 Cyon Therapeutics Company Information
  63. 8.11.2 Cyon Therapeutics Business Overview
  64. 8.11.3 Cyon Therapeutics PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Cyon Therapeutics PCSK9 Inhibitors Product Portfolio
  66. 8.11.5 Cyon Therapeutics Recent Developments
  67. 8.12 BMS
  68. 8.12.1 BMS Company Information
  69. 8.12.2 BMS Business Overview
  70. 8.12.3 BMS PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BMS PCSK9 Inhibitors Product Portfolio
  72. 8.12.5 BMS Recent Developments
  73. 8.13 Alnylam
  74. 8.13.1 Alnylam Company Information
  75. 8.13.2 Alnylam Business Overview
  76. 8.13.3 Alnylam PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Alnylam PCSK9 Inhibitors Product Portfolio
  78. 8.13.5 Alnylam Recent Developments
  79. 8.14 Affiris
  80. 8.14.1 Affiris Company Information
  81. 8.14.2 Affiris Business Overview
  82. 8.14.3 Affiris PCSK9 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Affiris PCSK9 Inhibitors Product Portfolio
  84. 8.14.5 Affiris Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PCSK9 Inhibitors Value Chain Analysis
  2. 9.1.1 PCSK9 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PCSK9 Inhibitors Production Mode & Process
  6. 9.2 PCSK9 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PCSK9 Inhibitors Distributors
  9. 9.2.3 PCSK9 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst